- ISIN
- US38341P1021
- CUSIP
- 38341P102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 8, 2019
Highlights
- Market Cap
- $46.87M
- Enterprise Value
- $207.82M
- EPS (TTM)
- -$0.79
- Total Revenue (TTM)
- $55.54M
- Gross Profit (TTM)
- $38.36M
- EBITDA (TTM)
- -$171.46M
- Year Range
- $0.16 - $3.87
- Target Price
- $0.77
- ROA (TTM)
- -139.95%
- ROE (TTM)
- 111.71%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
GOSS Performance Chart
Gossamer Bio, Inc. (GOSS) is down 93.5% since the beginning of the year. At $0 per share, GOSS is trading 94.8% below its 52-week high of $4. Investors who bought $1,000 worth of GOSS shares 5 years ago would now be looking at an investment worth $23.
Loading charts...
Returns By Period
Gossamer Bio, Inc. (GOSS) has returned -93.54% so far this year and -82.67% over the past 12 months.
Gossamer Bio, Inc.
- 1D
- 1.06%
- 1M
- -45.86%
- YTD
- -93.54%
- 6M
- -93.30%
- 1Y
- -82.67%
- 3Y*
- -46.54%
- 5Y*
- -52.78%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- 0.13%
- 1M
- 5.25%
- YTD
- 11.16%
- 6M
- 11.43%
- 1Y
- 28.20%
- 3Y*
- 21.12%
- 5Y*
- 12.66%
- 10Y*
- 13.75%
GOSS Monthly Returns History
Based on dividend-adjusted daily data since Feb 8, 2019, GOSS's average daily return is -0.02%, while the average monthly return is -1.04%.
Historically, 44% of months were positive and 56% were negative. The best month was Feb 2024 with a return of +67.9%, while the worst month was Feb 2026 at -81.4%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 6 months.
On a daily basis, GOSS closed higher 47% of trading days. The best single day was Jul 13, 2022 with a return of +31.9%, while the worst single day was Feb 23, 2026 at -80.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -26.45% | -81.36% | -22.69% | 11.96% | -37.22% | -13.30% | -93.54% | ||||||
| 2025 | 9.84% | 23.79% | -10.57% | -7.27% | 8.82% | 10.81% | 65.85% | 21.08% | 6.48% | -6.84% | 36.33% | -7.19% | 242.69% |
| 2024 | -7.95% | 67.86% | -16.31% | -39.83% | -16.90% | 52.69% | 0.27% | -2.82% | 12.37% | -10.99% | -20.50% | 29.60% | -0.87% |
| 2023 | 21.66% | -34.47% | -27.17% | 2.38% | 3.88% | -10.45% | 12.50% | -22.96% | -19.92% | -39.96% | 56.44% | 16.66% | -57.95% |
| 2022 | -15.21% | -5.84% | -3.88% | -20.39% | 2.03% | 18.72% | 34.17% | 24.22% | -14.12% | -7.35% | -22.88% | -74.65% | -80.81% |
| 2021 | 4.45% | -6.93% | -1.60% | -6.59% | -1.97% | -4.13% | -3.20% | 26.46% | 26.46% | -1.19% | -12.72% | 4.34% | 16.96% |
Benchmark Metrics
Gossamer Bio, Inc. has an annualized alpha of -22.38%, beta of 1.21, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since February 11, 2019.
- This stock participated in 231.28% of S&P 500 Index downside but only 61.96% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -22.38%
- Beta
- 1.21
- R²
- 0.06
- Upside Capture
- 61.96%
- Downside Capture
- 231.28%
Return for Risk
Risk / Return Rank
GOSS ranks 13 for risk / return — in the bottom 13% of stocks on our site. This means you're taking on significantly more risk than the returns justify. Consider whether the potential upside is worth the volatility, or explore alternatives with better risk / return profiles.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Gossamer Bio, Inc. (GOSS) and compare them to S&P 500 Index.
| GOSS | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.64 | 2.39 | -3.03 |
Sortino ratioReturn per unit of downside risk | -0.37 | 3.25 | -3.62 |
Omega ratioGain probability vs. loss probability | 0.94 | 1.43 | -0.50 |
Calmar ratioReturn relative to maximum drawdown | -0.87 | 3.11 | -3.99 |
Martin ratioReturn relative to average drawdown | -1.62 | 14.38 | -16.00 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Gossamer Bio, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Gossamer Bio, Inc. was 99.28%, occurring on May 18, 2026. The portfolio has not yet recovered.
The current Gossamer Bio, Inc. drawdown is 99.25%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.28%May 2026 | 6y 5mo | — | 6y 5moDec 2019 - now |
2019 bear market2019 | -38.15%Oct 2019 | 7mo 16d | 1mo 9d | 8mo 25dFeb 2019 - Nov 2019 |
2019 pullback2019 | -5.01%Dec 2019 | 0s | 5d | 5dDec 2019 - Dec 2019 |
2019 pullback2019 | -4.97%Feb 2019 | 0s | 1d | 1dFeb 2019 - Feb 2019 |
2019 pullback2019 | -3.14%Dec 2019 | 0s | 2d | 2dDec 2019 - Dec 2019 |
Drawdown Indicators
| GOSS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.28% | -56.78% | -42.50% |
Max Drawdown (1Y)Largest decline over 1 year | -94.92% | -9.10% | -85.82% |
Max Drawdown (3Y)Largest decline over 3 years | -94.92% | -18.90% | -76.02% |
Max Drawdown (5Y)Largest decline over 5 years | -98.70% | -25.43% | -73.27% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.25% | 0.00% | -99.25% |
Average DrawdownAverage peak-to-trough decline | -71.36% | -10.72% | -60.64% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 50.91% | 1.97% | +48.94% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Gossamer Bio, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Gossamer Bio, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for GOSS relative to other companies in the Biotechnology industry. Currently, GOSS has a P/S ratio of 0.8. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with GOSS
Add Gossamer Bio, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with GOSS